Kiaan’s Story
Kiaan’s story, by his mother “I wish people understood that rare doesn’t mean less real“…
-
-
May 2025 Cure GM1 Catalyst
As May begins, we’re filled with anticipation for GM1 Awareness Day on May 23rd. This is a month-long effort to shine a light on GM1 gangliosidosis and the remarkable community that surrounds it. We’ve submitted 12 proclamation requests to officials across the country.
-
Peyton’s Story
Peyton Claire’s story, by her mom “The light she has brought into our lives has…
-
April 2025 Cure GM1 Catalyst
Ten years ago this month, on April 17, 2015, the U.S. government approved the Cure GM1 Foundation to be the first and only 501(c)(3) entirely dedicated to GM1 gangliosidosis research, drug development and awareness. Over the course of a decade, our efforts have grown significantly. What began as a more personal search for hope became a global movement that has transformed the landscape for this rare disease.
-
Carter Michael’s Story
Carter’s story, by his mother “Carter Michael was diagnosed with GM1. He was our precious…
-
March 2025 Cure GM1 Catalyst
Help us make history by getting May 23rd, 2025 officially recognized as GM1 Gangliosidosis Awareness Day in your state! We’ve prepared all the materials you need – proclamation requests, supporting documents, and step-by-step guidance. Many states require submissions months in advance, so we need to start acting now!
-
Gael’s Story
Gael’s story, by his mother “Gael was diagnosed with Type 1 infantile GM1 on his…
-
February 2025 Cure GM1 Catalyst
This month is all about love, awareness, and action as we celebrate Valentine’s Day and Rare Disease Month. We are also celebrating our founder Christine’s daughter’s 17th birthday. For all families with children impacted by GM1, each birthday is a celebration, but the passage of time and the progression of the disease marks these milestones.
-
GM1 Research: Cure GM1 Invests $400,000 to Advance Development of Enzyme Replacement Therapy
Cure GM1 is dedicated to investing in research, seeding new projects, and to the development of multiple treatment modalities for GM1 gangliosidosis. In collaboration with our advisors and consultants, who have decades of experience in biotech and research, Cure GM1 has selected a contract research organization (CRO) to further the development of enzyme replacement therapy (ERT).